Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 7;39(10):110929.
doi: 10.1016/j.celrep.2022.110929.

Localized pmrB hypermutation drives the evolution of colistin heteroresistance

Affiliations

Localized pmrB hypermutation drives the evolution of colistin heteroresistance

Natalia Kapel et al. Cell Rep. .

Abstract

Colistin has emerged as an important last line of defense for the treatment of infections caused by antibiotic-resistant gram-negative pathogens, but colistin resistance remains poorly understood. Here, we investigate the responses of ≈1,000 populations of a multi-drug-resistant (MDR) strain of P. aeruginosa to a high dose of colistin. Colistin exposure causes rapid cell death, but some populations eventually recover due to the growth of sub-populations of heteroresistant cells. Heteroresistance is unstable, and resistance is rapidly lost under culture in colistin-free medium. The evolution of heteroresistance is primarily driven by selection for heteroresistance at two hotspot sites in the PmrAB regulatory system. Localized hypermutation of pmrB generates colistin resistance at 103-104 times the background resistance mutation rate (≈2 × 10-5 per cell division). PmrAB provides resistance to antimicrobial peptides that are involved in host immunity, suggesting that this pathogen may have evolved a highly mutable pmrB as an adaptation to host immunity.

Keywords: AMR; CP: Microbiology; Pseudomonas aeruginosa; antibiotic resistance; colistin; evolutionary rescue; experimental evolution; heteroresistance; hypermutability; mutation rate.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Figures

None
Graphical abstract
Figure 1
Figure 1
Population responses to colistin treatment Independent cultures of strain EP67 (n = 100) were inoculated into culture medium supplemented with colistin (2 mg/L). (A) Viable cell titer (n = 100; ±95% confidence interval [CI]) over the first 8 h of incubation. (B) Proportion of cultures (n = 100; ±95% CI) showing detectable growth over time, with a minimal limit of detection of 400 CFUs/culture. (C) Distribution of viable cell titer in cultures showing growth at 8, 24, and 48 h. The limits of detection in this assay were 400–8000 CFUs.
Figure 2
Figure 2
Testing the stability of colistin resistance Independent cultures of EP67 were incubated with colistin for 24 h, to select for resistance (n = 171). Cultures were then transferred to LB to allow resistant populations to expand. Recovered populations were then passaged into medium with LB or LB + colistin to test the stability of colistin resistance. After each passage, cultures diluted 10-fold and spotted out on LB agar plates to determine population viability, as determined by confluent colony growth.

Similar articles

Cited by

References

    1. Andersson D.I., Hughes D. Gene amplification and adaptive evolution in bacteria. Annu. Rev. Genet. 2009;43:167–195. doi: 10.1146/annurev-genet-102108-134805. - DOI - PubMed
    1. Andersson D.I., Nicoloff H., Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat. Rev. Microbiol. 2019;17:479–496. doi: 10.1038/s41579-019-0218-1. - DOI - PubMed
    1. Balaban N.Q., Helaine S., Lewis K., Ackermann M., Aldridge B., Andersson D.I., Brynildsen M.P., Bumann D., Camilli A., Collins J.J., et al. Definitions and guidelines for research on antibiotic persistence. Nat. Rev. Microbiol. 2019;17:441–448. doi: 10.1038/s41579-019-0196-3. - DOI - PMC - PubMed
    1. Baldi D.L., Higginson E.E., Hocking D.M., Praszkier J., Cavaliere R., James C.E., Bennett-Wood V., Azzopardi K.I., Turnbull L., Lithgow T., et al. The type II secretion system and its ubiquitous lipoprotein substrate, SslE, are required for biofilm formation and virulence of enteropathogenic Escherichia coli. Infect. Immun. 2012;80:2042–2052. doi: 10.1128/IAI.06160-11. - DOI - PMC - PubMed
    1. Barrick J.E., Colburn G., Deatherage D.E., Traverse C.C., Strand M.D., Borges J.J., Knoester D.B., Reba A., Meyer A.G. Identifying structural variation in haploid microbial genomes from short-read resequencing data using breseq. BMC Genomics. 2014;15:1039. doi: 10.1186/1471-2164-15-1039. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources